A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine -- approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo -- remains fully protective against disease in experimentally infected monkeys, according to scientists. The investigators completed the dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16.
